These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30274248)

  • 1. Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data.
    Sorokin M; Kholodenko R; Suntsova M; Malakhova G; Garazha A; Kholodenko I; Poddubskaya E; Lantsov D; Stilidi I; Arhiri P; Osipov A; Buzdin A
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30274248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation.
    Sorokin M; Kholodenko R; Grekhova A; Suntsova M; Pustovalova M; Vorobyeva N; Kholodenko I; Malakhova G; Garazha A; Nedoluzhko A; Vasilov R; Poddubskaya E; Kovalchuk O; Adamyan L; Prassolov V; Allina D; Kuzmin D; Ignatev K; Osipov A; Buzdin A
    Oncotarget; 2018 Jan; 9(4):5111-5124. PubMed ID: 29435166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data.
    Tkachev V; Sorokin M; Garazha A; Borisov N; Buzdin A
    Methods Mol Biol; 2020; 2063():235-255. PubMed ID: 31667774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
    Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
    J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
    Venkova L; Aliper A; Suntsova M; Kholodenko R; Shepelin D; Borisov N; Malakhova G; Vasilov R; Roumiantsev S; Zhavoronkov A; Buzdin A
    Oncotarget; 2015 Sep; 6(29):27227-38. PubMed ID: 26317900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
    Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
    Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
    Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel Structures.
    Mason DJ; Eastman RT; Lewis RPI; Stott IP; Guha R; Bender A
    Front Pharmacol; 2018; 9():1096. PubMed ID: 30333748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
    Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
    Olaussen KA; Commo F; Tailler M; Lacroix L; Vitale I; Raza SQ; Richon C; Dessen P; Lazar V; Soria JC; Kroemer G
    Oncogene; 2009 Dec; 28(48):4249-60. PubMed ID: 19749798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.